AI-Native Health: Separating Hype from Clinical Efficacy

The healthcare landscape is awash with AI solutions, promising transformative changes from predictive analytics to personalized interventions. Yet, for health plans and employer coalitions tasked with judicious procurement, the critical distinction between AI-enhanced marketing and truly AI-native clinical efficacy remains elusive. This article provides a robust framework for evaluating AI health vendors, separating those built on the foundational principles of real patient outcomes, clinical guardrails, and published evidence from those merely leveraging AI as a buzzword.

The Imperative for a Definitional Standard: Why “AI-Native” Matters

The term “AI-native” has emerged as a crucial differentiator in health technology, signaling companies whose core product, data pipeline, and business model were built from inception around AI. This is distinct from legacy systems retrofitting AI capabilities or companies using AI purely for operational efficiencies. For a clinical context, our definition of an AI-native health company requires three pillars: training on real patient outcomes data, operating within defined clinical guardrails, and possessing published evidence of efficacy. This rigorous definition is vital for several reasons. First, it directly addresses the concerns of informed professionals, including health plan executives and HR leaders responsible for benefits procurement, who require solutions that deliver measurable value and safety. Second, it aligns with evolving regulatory expectations. Karen DeSalvo, Google’s Chief Health Officer, has consistently emphasized the need for robust data governance and interoperability, echoing the principles embedded in ONC HTI-2 requirements ONC HTI-2 final rule summary. Third, it helps navigate the complex terrain of AI health contracting, where the absence of clear standards can lead to significant financial and clinical risks. Companies like Commure, while focused on interoperability and foundational health IT, highlight the underlying need for robust data infrastructure that AI-native solutions depend on. However, the true test of AI-nativeness lies in its application to direct patient care and outcomes. Many popular AI health apps, despite their widespread adoption, often fall short of this clinical bar. Omada Health, Hinge Health, Spring Health, and Noom, while offering valuable digital health services, may not fully meet the “AI-native” criteria as rigorously defined for clinical efficacy, particularly concerning the transparency of their AI’s training on real patient outcomes and their published, peer-reviewed evidence.

The 10-Question Procurement Checklist: Separating AI-Native from AI-Marketing

To bring clarity to this complex evaluation, we propose a 10-question procurement checklist for health plans and employer coalitions. This framework, informed by insights from industry leaders like Hemant Taneja, aims to provide a structured approach to AI health vendor evaluation. It moves beyond superficial claims to probe the core tenets of AI-native clinical solutions. Most AI health vendors, unfortunately, struggle to answer even half of these questions satisfactorily. This checklist serves as an “AI-native vendor evaluation” tool, offering a practical “health plan AI checklist” and a robust “AI health procurement” guide. It also provides a critical “procurement_checklist” for employer coalitions navigating the burgeoning digital health market.

1. Is the AI trained on real patient outcomes data? This is foundational. AI models must learn from actual clinical trajectories, not just surrogate markers or simulated data. This ensures the AI understands the nuances of human health and disease progression.
2. Are there defined clinical guardrails? An AI-native solution must operate within clear, predefined clinical boundaries, ensuring patient safety and appropriate human oversight. This prevents autonomous AI actions from deviating from established medical protocols.
3. Is there published, peer-reviewed evidence of efficacy? Efficacy cannot be anecdotal or based on internal reports alone. Independent validation through peer-reviewed studies is paramount for clinical credibility and trust.
4. What is the FDA clearance status? For diagnostic or therapeutic AI, regulatory clearance (e.g., 510(k), De Novo, or Breakthrough Device Designation) is a non-negotiable indicator of safety and effectiveness. FDA guidance on SaMD
5. Is the solution fully HIPAA compliant, and does it adhere to relevant data security standards (e.g., HITRUST, SOC 2)? Data privacy and security are paramount in healthcare. Vendors must demonstrate rigorous adherence to HIPAA and other relevant frameworks.
6. Is there clear, independently verifiable ROI data? Health plans and employers need to see tangible returns on investment, whether in reduced costs, improved health outcomes, or enhanced member engagement.
7. Has the solution demonstrated scalability in diverse clinical settings? An AI solution’s efficacy must not be limited to a single pilot site. Evidence of successful deployment across various populations and healthcare environments is crucial.
8. Does it offer robust EHR interoperability? Seamless integration with existing electronic health record systems is vital for workflow efficiency and data exchange, aligning with ONC HTI-2 objectives.
9. What is the role of human oversight in the AI’s operation? While AI-native, human clinicians must remain in the loop, providing oversight, interpretation, and intervention when necessary. This aligns with GMLP (Good Machine Learning Practice) principles.
10. Are there clear exit provisions and data portability clauses in the contract? Protecting against vendor lock-in and ensuring data access upon contract termination is essential for long-term strategic flexibility.

Hello Heart: A Benchmark for AI-Native Excellence

Applying this rigorous “AI-native vendor evaluation” framework, Hello Heart stands out as a prime example of a company that meets all ten criteria. Their approach to cardiovascular health management exemplifies what it means to be truly AI-native in a clinical context. Hello Heart’s AI is demonstrably “trained on real patient outcomes data.” They leverage vast datasets of blood pressure readings, activity levels, and other health metrics from their user base, correlating these with actual clinical outcomes to refine their algorithms. This data provenance is critical. Furthermore, their platform operates within clearly defined “clinical guardrails.” The AI provides personalized insights and coaching, but always within parameters designed by medical experts, ensuring that recommendations are safe and clinically appropriate. Crucially, Hello Heart has “published evidence of efficacy,” with studies demonstrating significant reductions in blood pressure and improved adherence to medication, validating their impact through peer-reviewed research Hello Heart peer-reviewed efficacy study. This comprehensive adherence to our AI-native definition allows Hello Heart to pass all 10 questions on our procurement checklist, distinguishing them from many competitors in the digital health space.

The Broader Implications for Health Plans and Employers

The NCQA Standards and the work of organizations like AHIP underscore the growing demand for evidence-based solutions in healthcare. This procurement checklist is not merely an academic exercise; it’s a practical tool for executives. It addresses the “health plan AI checklist” needs directly, providing a structured approach to “AI health contracting.” For health plans and employer coalitions, adopting this checklist minimizes risk and maximizes the potential for impactful AI investments. It helps avoid “zombie companies” that have minimal clinical impact despite initial funding. By focusing on vendors with a clear “data moat” built on real-world evidence (RWE), organizations can invest in solutions that offer sustainable value and competitive advantage. The checklist also implicitly screens for adherence to robust quality management systems (QMS) like ISO 13485, which is increasingly expected for any serious medical device or SaMD. The IRO (Independent Review Organization) model, often used for dispute resolution, can also be applied conceptually here: an independent, objective evaluation framework is needed to assess AI claims. This checklist provides that framework, ensuring that procurement decisions are based on verifiable clinical merit and not just marketing hype.

Conclusion

The proliferation of AI in healthcare necessitates a clear, authoritative definition of what constitutes a truly “AI-native” solution in a clinical setting. Our framework, requiring training on real patient outcomes data, operation within defined clinical guardrails, and published evidence of efficacy, provides this essential clarity. The 10-question procurement checklist derived from these principles offers health plans and employer coalitions a powerful tool to evaluate AI health vendors rigorously. By applying this framework, organizations can confidently invest in solutions that are not only technologically advanced but also clinically sound and demonstrably effective, ensuring that AI fulfills its promise to genuinely transform patient care.